References
- 1BalintB, VincentA, MeinckH-M, IraniSR, BhatiaKP Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain 2018;141(1):13–36. doi: 10.1093/brain/awx18929053777
- 2BinksSNM, KleinCJ, WatersP, PittockSJ, IraniSR LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. J Neurol Neurosurg Psychiatry 2018;89(5):526–534. doi: 10.1136/jnnp-2017-31572029055902
- 3IraniSR, MichellAW, LangB, PettingillP, WatersP, JohnsonMR, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69(5):892–900. doi: 10.1002/ana.2230721416487
- 4IraniSR, StaggCJ, SchottJM, RosenthalCR, SchneiderSA, PettingillP, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013;136(Pt 10):3151–3162. doi: 10.1093/brain/awt21224014519
- 5DamatoV, BalintB, KienzlerAK, IraniSR The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders. Mov Disord 2018;33(9):1376–1389. doi: 10.1002/mds.27446 [Epub 2018 Sep 14].30218501
- 6GadothA, PittockSJ, DubeyD, McKeonA, BrittonJW, SchmelingJE, et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol 2017 7;82(1):79–92. doi: 10.1002/ana.2497928628235
- 7ThompsonJ, BiM, MurchisonAG, MakuchM, BienCG, ChuK, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 2018;141(2):348–356. doi: 10.1093/brain/awx32329272336
- 8GadothA, ZekeridouA, KleinCJ, ThoresonCJ, MajedM, DubeyD, et al. Elevated LGI1-IgG CSF index predicts worse neurological outcome. Ann Clin Transl Neurol 2018;5(5):646–650. doi: 10.1002/acn3.56129761127